Home › Compare › DGTHF vs ABBV
DGTHF yields 287.77% · ABBV yields 3.06%● Live data
📍 DGTHF pulled ahead of the other in Year 1
Combined, DGTHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DGTHF + ABBV for your $10,000?
DGTL Holdings Inc. incubates digital media and advertising technology companies using artificial intelligence in Canada and internationally. The company accelerates commercialized enterprise level software as-a-service companies through capitalization structures, including investment, mergers and acquisitions, earnouts, and licensing structures. It also offers Hashoff, a software-as-a-service platform provides micro-influencer marketing for brands; and TotalSocial, a platform-as-a-service focuses on the entire social ecosystem by combining powerful on-line and off-line data with predictive analytics. In addition, the company provides social intelligence using proprietary data and methodology for various brands and companies. The company was formerly known as Conscience Capital Inc. and changed its name to DGTL Holdings Inc. in July 2020. DGTL Holdings Inc. was incorporated in 2018 and is headquartered in Toronto, Canada.
Full DGTHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.